1. Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
- Author
-
Moodie, Zoe, primary, Dintwe, One, additional, Sawant, Sheetal, additional, Grove, Doug, additional, Huang, Yunda, additional, Janes, Holly, additional, Heptinstall, Jack, additional, Omar, Faatima Laher, additional, Cohen, Kristen, additional, De Rosa, Stephen C, additional, Zhang, Lu, additional, Yates, Nicole L, additional, Sarzotti-Kelsoe, Marcella, additional, Seaton, Kelly E, additional, Laher, Fatima, additional, Bekker, Linda Gail, additional, Malahleha, Mookho, additional, Innes, Craig, additional, Kassim, Sheetal, additional, Naicker, Nivashnee, additional, Govender, Vaneshree, additional, Sebe, Modulakgotla, additional, Singh, Nishanta, additional, Kotze, Philip, additional, Lazarus, Erica, additional, Nchabeleng, Maphoshane, additional, Ward, Amy M, additional, Brumskine, William, additional, Dubula, Thozama, additional, Randhawa, April K, additional, Grunenberg, Nicole, additional, Hural, John, additional, Kee, Jia Jin, additional, Benkeser, David, additional, Jin, Yutong, additional, Carpp, Lindsay N, additional, Allen, Mary, additional, D’Souza, Patricia, additional, Tartaglia, James, additional, DiazGranados, Carlos A, additional, Koutsoukos, Marguerite, additional, Gilbert, Peter B, additional, Kublin, James G, additional, Corey, Lawrence, additional, Andersen-Nissen, Erica, additional, Gray, Glenda E, additional, Tomaras, Georgia D, additional, and McElrath, M Juliana, additional
- Published
- 2022
- Full Text
- View/download PDF